Facebook
Twitter
LinkedIn
Forward
Struggling to Breathe: The Patient Journey to Diagnosis and Treatment of Interstitial Lung Disease
This is a 1.25-hour on-demand activity that provides guidance to primary care clinicians who manage care and support for patients with ILDs and their caregivers. The five (5) member faculty is comprised of a primary care physician (PCP), a pulmonologist, an ILD clinical pharmacy specialist, an ILD nurse, and an actual patient with ILD.
This multidisciplinary roundtable is delivered as a role-played patient-case through several office visits. The primary care physician interviews an actual ILD patient and consults with the interprofessional team-members on management and best treatment methods. Also included are video vignettes of actual patients to provide the patient's perspective.
Overview
Interstitial lung disease (ILD), a restrictive lung disease, comprises a heterogeneous group of over 200 distinctive lung disorders characterized by inflammation and scarring (fibrosis) of the interstitium of the lung. The interstitium of the lung is a microscopic area within the walls of the alveoli (air sacs) between the membrane of the air sac and the membrane of the surrounding blood vessels. Under normal physiologic circumstances, oxygen passes easily from inside the air sac, through its membrane, across the interstitium and through the membrane of the blood vessel and circulates throughout the body. In ILDs, the fibrosis thickens the interstitium and restricts their expansion limit, leading to lower lung capacity and diminished oxygen diffusion to the bloodstream. The most common symptoms of ILD are shortness of breath, often accompanied by dry cough, chest discomfort, fatigue, and potential weight loss. If left untreated, severe symptoms can include hypertension, heart failure, or respiratory failure.
ILDs are associated with significant clinical and economic burden. In 2019, the estimated total cases of ILD was 654,841 in the United States (US). The estimated crude prevalence of ILDs is about 400 (180 males and 220 females) per 100,000 of the US population.
Target Audience
This activity has been designed to meet the educational needs of primary care physicians, physicians, physician assistants, nurses, and nurse practitioners.
Learning Objectives
At the conclusion of this activity, participants will be able to:
1. Recognize the epidemiology, disease burden, and signs and symptoms of ILD.
2. Identify risk factors and/or comorbidities associated with ILD.
3. Identify strategies for timely and accurate ILD diagnosis and referral, including the use of appropriate tests and procedures.
4. Commit to strategies optimizing interprofessional, multidisciplinary communication among patients, caregivers, and the healthcare team that is culturally and linguistically appropriate.
5. Recognize aspects of the socioeconomic and health disparities impacting optimal ILD management.
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Additional Information
| Attachment | Size |
|---|---|
 Interstital Lung Disease Slide Presentation.pdf | 3.35 MB |
 Interstital Lung Disease Resources.docx | 15.39 KB |
Speakers
Andrew L. Botieri
Scleroderma Survivor
Author and Keynote Speaker
Author of A Celebration of Life: A Story of Hope, a Miracle, and the Power of
Attitude. A story of his scleroderma journey.
Finn J. Hawkins, M.B. B.Ch.
Pulmonary, Allergy, Sleep & Critical Care Medicine
Dept of Medicine
Assistant Professor of Medicine
Boston University Chobanian & Avedisian School of Medicine
Boston, MA
Amanuel Kehasse, PharmD, PhD
Course Director
Ambulatory Clinical Manager – Specialty Pharmacy
Dermatology and Interstitial Lung disease
Boston Medical Center Health System
Boston, MA
Dina Riley, RN, BSN
PH/ILD Nurse Coordinator
Pulmonary Clinic Boston Medical Center
Boston, MA
Jason Worcester, MD
Medical Director, Boston Accountable Care Organization
Boston Medical Center Health System
Clinical Associate Professor of Medicine
Boston University Chobanian & Avedisian School of Medicine
Boston, MA
Accreditor Disclosure Policy
Boston University Chobanian and Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian and Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.
Program Faculty Disclosures
Dr. Amanuel Kehasse, CME Course Director, is a consultant for Novartis.
Dr. Hawkins, Dr. Worcester, Ms. Dina Riley and Mr. Andrew Botieri have no relevant financial relationships to disclose.
Off-Label Discussion
The faculty members do not plan on discussing unlabeled/investigational uses of a commercial product.
Accreditor Disclosures
The following planning committee members from Boston University Chobanian and Avedisian School of Medicine’s Office of Continuing Medical Education have no relevant financial relationships to disclose:
Michael Burk, BS – Senior Program Manager
Brian Jack, MD – American Academy of Family Physician (AAFP) and CME Accreditation Reviewer
Joint Accreditation
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The Boston University Chobanian & Avedisian School of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Nursing Contact Hours: 1.25, all of which is eligible for pharmacology credit.
American Academy of Family Physicians (AAFP) Accreditation
The AAFP has reviewed Struggling to Breathe: The Patient Journey to Diagnosis and Treatment of Interstitial Lung Disease and deemed it acceptable for up to 1.00 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 05/15/2023 to 05/15/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AAFP Prescribed
- 1.25 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 ANCC
- 1.25 ANCC Pharmacology
- 1.25 Participation